Eromycin 3% w/v

Lotion

Pack Size : 1 Lotion x 1 Packate

Generics : Erythromycin solution

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 120.00

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - Eromycin 3% w/v

Description

Generic Name

Erythromycin solution

Precaution

Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. Lactation: Unknown if excreted in breast milk; use with caution

Indication

Acne

Contra Indication

Hypersensitivity; porphyria; hepatic impairment; pregnancy.

Dose

N/A

Side Effect

Contact sensitization,Dryness,Erythema,Skin irritation,Skin tenderness Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.

Pregnancy Category

Name : B

Description

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Mode of Action

Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.

Interaction

Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants. Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.

Pregnancy Category Note

Pregnancy Category: B Lactation: Unknown if excreted in breast milk; use with caution

Adult Dose

Topical/Cutaneous Acne Adult: Apply onto affected areas 1-2 times daily. Discontinue treatment if condition worsens or if there is no improvement after 6-8 wk of continuous usage. Max duration: 6 mth.

Child Dose

Safety and efficacy not established

Renal Dose

N/A

Administration

Apply to affected areas after skin is thoroughly washed and patted dry

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.